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DDespite these limitations, PhotoFix pericardium trended
to be the better alternative in patients in whom autologous
tissue cannot be used. PhotoFix is an alternative to glutaral-
dehyde fixation, which uses dye-mediated photo-oxidation
rather than chemical cross-linking. Photo-oxidized bovine
pericardium is similar to untreated tissue in texture, pliabil-
ity, and shrinkage temperature, but unlike untreated tissue, it
possesses chemical, enzymatic, and in vivo stability. It is
thus non-immunogenic, biocompatible, and, unlike
glutaraldehyde-treated tissues, noncalcifying and noncyto-
toxic, thus allowing endothelization.23 Its use in valve recon-
struction has been limited24 because of poor results with
PhotoFix-based bioprostheses,25 although this was shown
to be due to valve design rather than fixation technique.
Study Limitations
This study has several limitations. It is a retrospective and
nonrandomized comparison of aortic cusp extension mate-
rials and represents a 15-year period of evolving experience
with AV repair. As such, any inferences drawn from these
data are limited by confounding variables, such as extent
of cusp disease, severity of preoperative AI, need for MV
or tricuspid repair, and duration of follow-up, which are dif-
ferently distributed between study groups. Our sample size
also limits our ability to perform extensive statistical adjust-
ments for these differences. Finally, follow-up echocardio-
graphic data were interpreted and analyzed, for the most
part, by the referring cardiologist in the patients’ country
of origin. This introduces the risk of estimator bias, because
the echocardiographic images could not be interpreted by an
independent echocardiography laboratory blinded to the sur-
gery, extension material, and clinical outcome.
CONCLUSIONS
Aortic cusp extension provides adequate valve repair in
a large proportion of children with rheumatic aortic regurgi-
tation. Fresh autologous and PhotoFix bovine pericardium
showed better durability, requiring fewer reoperations than
glutaraldehyde pericardium at midterm.
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Dr Emile Bacha (New York, NY). Although retrospective, this is
an important article for the following reasons: It comes from a cen-
ter with a large experience with AV repair, thus having digested the
learning curve. It reports on a homogeneous group of patients, all of
whom had rheumatic fever. It focuses on patch material, something
that hasn’t been done really in the past series.
It seems to me that AV repair as a technique is maturing and
much less controversial. However, it’s remarkable to note thatery c October 2010
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Doutcomes remain kind of stuck at 20% to 30% reoperation rate and
roughly 70% freedom from reoperation at 7 to 10 years. Thus, there
is still a lot of room for improvement, and one improvement could
come from better patch material. I have a few questions. Please con-
firm your current choice of patch material at this point in time.
Dr Myers. Fresh autologous pericardium.
Dr Bacha.What will be your second choice if the pericardium is
involved with the rheumatic carditis?
Dr Myers If it were available, we would use PhotoFix pericar-
dium because in our experience it doesn’t calcify or retract, and it
stays pretty much as is during its life. So that would be our second
choice if it’s not possible to use autologous pericardium.
Dr Bacha. Because it’s not available, what would you use then?
Dr Myers. Unfortunately, glutaraldehyde-fixed bovine pericar-
dium is our current strategy.
Dr Bacha. I was intrigued by the ostial occlusions that you
noticed in those 2 patients. Can you expand a bit on that, where
the patch is too long?
Dr Myers.We used our standard described technique for sizing
the patches. In these 2 cases, after releasing the crossclamp, we had
persistent ventricular fibrillation that was resistant to any form of
treatment. In these cases we reclamped the aorta, arrested the heart
and explored the extensions, and removed 1 mm of height from
each extension. In each case, the patients were weaned off bypass
without any trouble.
Dr Bacha. Was there any echo guidance with this? Could you
see that the patch extensions were occluding the ostium?
Dr Myers. Indeed, that was a help in the diagnosis.
Dr Bacha. Some people have recently advocated placing those
extension patches at the base of the cusp as opposed to on the free
edge of the cusp. In rheumatic fever you have a traction of the free
edge, but is that something that could be useful in this particular dis-
ease?
Dr Myers. That could be useful. From a technical standpoint,
we found it easier to work with the existing cusps, shaving them,
if necessary, to make them pliable. But it’s true that in our experi-
ence, for example, in the PhotoFix pericardium group, the mode
of recurrent regurgitation was annular dilation in 1 patient and
renewed retraction on the native cusps in 2 patients. One could hy-
pothesize that these 2 patients would not have required a reoperation
had they had their own cusps removed entirely and the valve
reconstructed completely from the base of the cusps.
Dr Bacha. What about the patient who presents with severe
aortic regurgitation and is hemodynamically unstable with active
rheumatic fever or unresolved rheumatic fever? Would you recom-
mend the AV repair in that situation?
Dr Myers. It depends entirely on how the tissues appear when
we look at the AV. Let’s say, ideally, yes. But we can, in those
cases, find that the aortic cusps are very friable and that sutures
do not hold very well on that. So our strategy would be to attempt
a repair; however, it’s not always technically feasible.
Dr Bacha. I would be careful with that, because if your rheu-
matic fever is not burnt out you may have rheumatic fever on the
repaired valve.
Dr Myers. On the extended cusps, absolutely.
Dr Gerhard Ziemer (Tuebingen, Germany). Dr Myers, you
have to be congratulated for your work and results. And obviouslyThe Journal of Thoracic and Cain medicine when you do something and have good results, it’s the
right thing.
However, I have a conceptual problem with what you’re doing
and claiming. With the use of fresh autologous pericardium in
this position, as you use in MVs, we know that fresh pericardium
retracts. So what is the trick or the reason that you replace your
cusps with fresh autologous pericardium and it doesn’t shrink.
Do you use a special size?
I can say in those MVs where I used pericardium and occasion-
ally forgot or glutaraldehyde wasn’t there, after 3 months I had
some leak because the pericardium was retracting. So why doesn’t
this happen in your cases?
DrMyers. In our experience, the mode of failure differs depend-
ing on the material, and it’s a choice of which is the best available
option. Fresh autologous pericardium retracts with time. With glu-
taraldehyde-fixed pericardium, we found that these rapidly calcify,
independently of the length of fixation.
Dr Ziemer. But you did not use autologous glutaraldehyde-
fixed pericardium. You only had bovine, and this is completely
different. Did you ever try fresh autologous glutaraldehyde-fixed
pericardium?
DrMyers.We have an initial, very limited experience with that,
and we had very rapid calcification in the aortic position, which is
why we abandoned that.
Dr Ziemer. Okay. Thank you.
Dr Muhammad Ali Mumtaz (Norfolk, Va). I have a couple of
comments and 1 question. I’m very curious to see, if you don’t have
an answer, if the audience or moderators might.
A number of studies, including one from Cleveland Clinic,
which I was part of, in which glutaraldehyde-treated pericardium,
autologous pericardium, was used, typically there is no early calci-
fication. Late retraction and scarring do happen.
But recently I had the misfortune, or fortune, to use CorMatrix,
which is an acellular submucosa of the intestine, in 2 patients. In the
second patient, the posterior commissure bicuspid valve dehisced at
the attachment. So I had to go back, and thinking I would replace
the valve, once I noticed that the commissure had dehisced, I essen-
tially just reattached it. But to my pleasant surprise, just as the
company says, the leaflets were entirely replaced by normal tissue.
I could not distinguish what was normal and what was not. So I’m
curious to know if you have entertained using that? Or if certainly
there is no pericardium, why not use CorMatrix (Atlanta,
Ga), which is acellular or decellularized submucosa of the
intestine?
If you don’t have experience, I’m just curious to know if the
moderators or anybody in the audience has and what have they
found in terms of their durability. I’ve only used it in the last
year, and so I really don’t have follow-up information.
Dr Myers. I have no experience with the CorMatrix in intracar-
diac situations, only as an extracardiac material (to minimize peri-
cardial adhesions). But I don’t know if one of the moderators has
experience with intracardiac use.
Dr Tweddell. I have no experience with it, but I think you’ve all
sort of hit on the point: It’s really a materials problem, right? You’re
able to reconstruct a competent valve at the end of the procedure;
it’s just trying to find something that will hold up and be as durable
as cusp tissue normally is.rdiovascular Surgery c Volume 140, Number 4 843
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DDr Bacha. I don’t have any experience either, but I’m thinking
along the same lines as well.
Dr A. Charles Yankah (Berlin, Germany). Why didn’t you
use anticalcification-treated glutaraldehyde to mitigate calcifica-
tion?
Dr Myers. That’s a good proposition. Unfortunately, it’s not
freely available in our center. And given our initial experience
with fresh autologous pericardium, which was relatively good to
the midterm, we continued on that line; but that is indeed a line
of thought that could be pursued.
DrYankah.Did you make any study on the immune response in
the explanted glutaraldehyde, just to identify any tissue reaction,
because this could trigger the left ventricular structural valve
deterioration and calcification.
Dr Myers. No, we did not. All we did was standard cross-
sections to get an idea of what was happening in terms of fibrotic
reaction, retraction, calcification, and so forth. We have not done
any more detailed immunologic research in that line.
Dr Yankah. In view of inflammation of the tissue, did you an-
ticipate or try to treat these patients with anti-inflammatory drugs?
Dr Myers. No, that is not part of our management. Of course,
with rheumatic fever or rheumatic heart disease, that is an ongoing
process and an issue over time, and that could be another line of
further research.
Dr Yankah. Did you put these patients on long-term penicillin
to prevent recurrence of rheumatic fever?
Dr Myers. Absolutely.
Dr Andres Jorge Schlichter (Buenos Aires, Argentina). I want
to congratulate you on a nice presentation, and I’m not going to ask
you anything about the technique because I’m a fan of autologous
fresh pericardium.
Where did you get this number of patients with rheumatic fever
who are so young in Switzerland? We don’t have them in Argen-
tina. We don’t have them in underdeveloped countries anymore.
An 8-year-old with aortic incompetence due to rheumatic fever is
extremely rare. We don’t have that in Argentina, and that’s an un-
derdeveloped country. There used to be rheumatic fever in Argen-
tina, but not anymore. What we usually observe now is aortic844 The Journal of Thoracic and Cardiovascular Surgincompetence caused by invasive cardiology (balloon dilation of
bicuspid valves). We don’t see these tricuspid valves. Did you
import these patients?
DrMyers. Indeed, they were imported. We work with a human-
itarian association, and we are a reference center for these patients.
Dr Schlichter. Okay. Excellent answer.
Dr Christian Brizard (Melbourne, Australia). We have used
the cusp extension technique in both Paris and Melbourne with au-
tologous pericardium treated with glutaraldehyde. In Melbourne
we operate on aboriginal patients, and the incidence of aortic regur-
gitation in this population is relatively high, but much lower than
mitral regurgitation. We have a ratio of 1:10 AV surgery compared
with MV surgery.
My question is relevant to the same topic as the previous ques-
tion. In Paris we operated on patients through the Chain of Hope,
or ‘‘La Chaine de L’Espoir,’’ and we received patients from North
Africa mostly. It is notoriously difficult to have follow-up infor-
mation on these patients. We had extensive experience with this
technique, and it seemed that at midterm follow-up we had
good results. But when you do obtain long-term follow-up of
these rheumatic patients, it’s not as shiny. Therefore, the current
recommendation of the Chain of Hope, when we receive similar
patients in France now, is to use mechanical valve replacement
rather than cusp extension. The mechanical valve in the aortic po-
sition may tolerate antiplatelet therapy in these countries and has
good outcome.
Dr Myers. Of course, in a long-term study such as this, the
quality of the data is of utmost importance. The humanitarian asso-
ciation with which we are working, Terre Des Hommes, has a sys-
tem in place that guarantees follow-up with cardiologists, often
trained by the association, in northern Africa who can perform
the follow-up and get the follow-up data. We are updated yearly
with their data and involved in any decisions on reoperations.
The long-term follow-up and results in these patients are of utmost
importance, especially when offering an option that has a 20% to
30% reoperation rate.
Dr Bacha. Thank you, Dr Myers. We’re over time, so we’re
going to have to move on.ery c October 2010
